Prenetics Q1 2026 Earnings: Record IM8 Revenue Growth and Raised Guidance

Prenetics Global Limited reported strong Q1 2026 financial results with total revenue of $36.0 million, driven by its IM8 health brand which generated $33.8 million in revenue, representing 23.1% sequential growth from Q4 2025 and nearly 6x year-over-year growth. The company raised its full-year 2026 IM8 revenue guidance to $190-210 million from $180-200 million previously. IM8 achieved record monthly revenue of approximately $16.7 million in May 2026, implying annualized recurring revenue of approximately $200 million. The company maintained a strong debt-free balance sheet with $56.0 million in cash and subsequently divested its digital asset holdings for $41.3 million. Prenetics also announced a $40 million share repurchase program and appointed Brian J. Rosin as CFO of IM8.